Future Seminar Dates
Monday 15th January 2018
Title: "PI3K in Immunity, Infection and Cancer"
Speaker: Professor Klaus Okkenhaug, University of Cambridge.
Venue: Lecture Theatre 3, F Floor Medical School.
Time: 12:30pm - 1:30pm
Abstract: The PI3K signalling pathway control many aspects of immune responses. The PI3Kδ isoform is selectively expressed cells of the immune system. Loss of PI3Kδ activity leads to impaired humoral immunity. However, loss of PI3Kδ in regulatory T cells can also contribute to enhanced immune responses, especially against cancer cells. Activated PI3Kδ syndrome is a primary immunodeficiency caused by mutations that lead to increased PI3Kδ activity. The fact that both loss of function and gain of function of PI3Kδ leads to immunodeficiency highlights how signalling pathways need to be dynamically regulated for normal immune cell function. Hyperactivity of PI3Kδ also leads to B cell transformation. Idelalisib is a PI3Kδ inhibitor, which has been approved for the treatment of certain B cell cancers. I will describe our approach to explore the roles of both loss and gain of PI3Kδ function in immunity, infection and cancer and discuss how PI3Kδ inhibitors for additional indications.
If you would like to meet with one of the speakers during their visit, please contact Victoria Palmer who will be able to assist.